BioMarin
History
| Year | Detail |
|---|---|
| 1997 | Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. |
| 2007 | BioMarin and IGAN Biosciences collaborated on developing an enzyme therapy to treat IgA Nephropathy, a rare and life-threatening kidney disease. |
| 2010 | To expand its core business portfolio, the company acquired ZyStor Therapeutics Inc., a privately held biotechnology company developing enzyme replacement therapies (ERT) for treating lysosomal storage disorders. |
| 2011 | The company acquired a bulk biologics manufacturing plant from Pfizer in Shanbally, Cork, Ireland, for $48.5 million to manufacture GALNS products. |
| 2020 | BioMarin and Deep Genomics collaborated to use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications. |
| 2021 | The company collaborated with Skyline Therapeutics, a gene and cell therapy company focused on developing novel treatments to discover, develop, and commercialize Adeno-associated virus (AAV) gene therapies to treat genetic cardiovascular diseases. |
BCC Research Beacon 